

For Immediate Release

MedX Health Establishes European Distribution Center

New Director of European Sales, Frank Raymakers, to Oversee Unit

Mississauga, ON – April 22, 2009 – MedX Health Corp., (TSXV.MDX) a global leader in developing drug free, non-invasive low level laser and light therapy for tissue repair and pain relief, today announced that the company has opened a European Distribution Center located in the Netherlands. Following receipt of the CE Mark approval to market and sell the family of MedX laser and light products in all 25 European Union (EU) and three European Free Trade Association Member (EFTA) states, MedX can now better serve its EU and EFTA customers. In addition, MedX announced the appointment of Frank Raymakers as Director of European Sales, to oversee operations.

Mecan b.v., a well established European medical device and supplies distributor will be providing logistics and warehouse services for the MedX European distribution center.

"We are very pleased to have been able to establish a distribution center so quickly after receiving the CE Mark," states Steve Guillen, president and CEO of MedX Health. "Having Frank on board will help us build a successful medical device distribution network in Europe. MedX's European launch will be one of the key drivers to our rapidly accelerating revenues in 2009."

As director, European Sales, Raymakers will build the network of EU distributors in various countries for both the medical and dental markets. In addition, he will be responsible for training and ongoing support for the MedX EU distributor network.

Prior to joining MedX, Raymakers established a record of success in building distribution networks with several medical device companies in Europe. Most recently, he served as director of area and dealer management in North-West Europe for EnviteC/Honeywell. Raymakers is a native of the Netherlands and speaks fluent Dutch, German and English.

About MedX

MedX Health is a global leader in the design, manufacturing and distribution of quality low level laser and light therapy technology for use in numerous medical settings that provide patients with non-invasive, drug-free solutions for improving clinical outcomes. MedX's innovative Laser/Light Therapy devices enhance the patient's quality of life and improve the standard of care for tissue repair and pain relief.

MedX is expanding its distribution network and marketing programs globally through strategic partnerships, while continuing to develop and acquire new dental, rehabilitation and wound care products. In particular, MedX plans to accelerate the development of a new product aimed at the rapidly-growing wound care market. Recently, MedX announced a new patent allowance for bone growth that will join several key existing patents, including "Photobandage" a new technology that allows a wound to be bathed in light and is designed to enhance the healing process. The Company



intends to license its proprietary wound care technologies to one or more major wound care companies for further development, marketing and commercialization.

About Mecan b.v.

Mecan b.v. is a well established European medical device and supplies distributor providing logistics and warehouse services for over 10 years for product manufacturers in the human and veterinary markets, including Henry Schein, Promhovet, S & B medvet, and Tecno-Gaz. Mecan provides the logistics, sales, and financial services for more than 10,000 products, and stocks 1,500 different products in their facility in the Netherlands.

Contacts:

Investors:

Steve Guillen President and Chief Executive Officer MedX Health Corp. Phone: (905)826-0766 info@medxhealth.com

Media:

Terri Clevenger Continuum Health Communications Phone (203) 227-0209 Email: <u>tclevenger@continuumhealthcom.com</u>

Europe:

Frank Raymakers Director European Sales Direct: 0031-73-6576976 Cell: 0031-623-407058 Email: <u>frank@medxhealth.com</u>

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Such forward-looking information may include statements regarding the Company's future plans, objectives, performance, growth, profits, operating expenses or its underlying assumptions. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "does not anticipate", or "believes"



or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", or "will be taken", "occur", or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of MedX to be materially different from those expressed or implied by such forward-looking information, including uncertainty of successful development of new products, uncertainty of successful manufacturing or marketing of products, uncertainty of commercial acceptance of products, uncertainty concerning governmental regulation, dependency on key employees and relationships, rapid technological changes, foreign currency fluctuations. MedX does not undertake to update any forward-looking information, except in accordance with applicable securities laws.